Comparison of the Clinical Features and Prognostic Value of Inflammation-Based Markers in Uterine Leiomyosarcoma

Yıl 2024, Cilt: 51 Sayı: 3, 325 - 332, 19.09.2024

Serhat Sekmek , Fahriye Tuğba Köş , Gökhan Uçar , Doğan Bayram , Burak Civelek

https://doi.org/10.5798/dicletip.1552473

Öz

Aim: Inflammation-related markers are the factors affecting prognosis in many types of cancer. In this study, we aimed to investigate the relationship between inflammation-related markers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) with prognosis of patients with uterine leiomyosarcoma (uLMS).
Methods: Patients diagnosed with uLMS were reviewed retrospectively. NLR, PLR, SII, and PNI values were calculated at the diagnosis and before treatment. Totally 35 patients were included in the study.
Results: Median overall survival (OS) in the low-NLR (<2.10) group was not reached using Kaplan-Meier analysis, whereas in the high-NLR (≥2.10) group, median OS was 41.6 months (95% CI:25.7 – 57.4) (p=0.019). Median OS in the low-PLR (<145) group could not be reached using Kaplan-Meier analysis, whereas, in the high-PLR (≥145) group, the median OS was 43.0 months (95% CI:21.9 – 64.1) (p=0.046). The median OS was 107.7 months (confidence interval not reached using Kaplan-Meier analysis) in the low-SII (<806) group, while the median OS was 43.0 months (95% CI:23.7 – 62.3) in the high-SII (≥806) group (p=0.039). In the low-PNI, (<53.7) group, the median OS was 53.2 months (95% CI:20.8 – 90.9), while in the high-PNI (≥53.7) group, the median OS was 41.6 months (0 – 94.0) (p=0.652). In multivariate analysis, mitotic count and NLR were observed as independent factors affecting prognosis in OS (p=0.012 and p=0.035).
Conclusions: NLR≥2.10 is an independent marker showing a poor prognosis in uLMS patients.

Anahtar Kelimeler

Neutrophil-lymphocyte ratio, uterine leiomyosarcoma, survival, prognosis

Kaynakça

• 1. Takehara K., Yamashita N, Watanabe R, et al. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma. Gynecol Oncol. 2020; 157: 115-120.
• 2. Kapp D.S., J.Y. Shin, and J.K. Chan. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112: 820-30.
• 3. Abeler V.M., Røyne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009; 54: 355-64.
• 4. Greer B.E., Koh WJ, Abu-Rustum N, et al. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009; 7: 498-531.
• 5. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003; 89: 460-9.
• 6. Mantovani A., Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436-44.
• 7. Cedrés S., Torrejon D, Martínez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. ClinTra nsl Oncol. 2012; 14: 864-9.
• 8. Kinoshita A., Onoda H, Imai N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012; 107: 88-93.
• 9. Chen J.H., Zhai ET, Yuan YJ, et al. Systemic immuneinflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017; 23:6261-72.
• 10. Hirahara N., Tajima Y, Fujii Y, et al. Preoperative Prognostic Nutritional Index Predicts Long-Term Surgical Outcomes in Patients with Esophageal Squamous Cell Carcinoma. World J Surg. 2018; 42:2199-208.
• 11. Yao Y., Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced nonsmall cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013; 62: 471-9.
• 12. Choi W.J., Cleghorn MC, Jiang H, et al. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Plateletto-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer. Ann Surg Oncol. 2015; 22: S603-13.
• 13. Asher V., Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011; 13: 499-503.
• 14. Szkandera J., Pichler M, Absenger G, et al. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg. 2014; 208: 210-4.
• 15. Yang C., Hu BW, Tang F, et al. Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: A Comprehensive Study Based on Meta-Analysis and Retrospective Single- Center Analysis. J Clin Med. 2022; 11(24): 7514
• 16. Zhou Y., M. Dai, and Z. Zhang. Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer:A Meta-Analysis. Front Oncol. 2022; 12: 814727.
• 17. Kos F.T., Hocazade C, Kos M, et al. Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer. Asian Pac J Cancer Prev. 2015; 16:3997-4002.
• 18. Bardakci M., Hafizoglu E, Kos FT, Uncu D. Does Prognostic Nutritional Index Predict Survival in Operated Papilla Vateri Tumors? A Single-centre Experience. J Coll Physicians Surg Pak. 2021. 31:1428-32.
• 19. Ayhan A., Gungorduk K, Khatib G, et al. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003. Curr Probl Cancer. 2021; 45: 100712.
• 20. Seagle B.L., Sobecki-Rausch J, Strohl AE, et al. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecol Oncol. 2017; 145: 61-70.